Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bone morphogenetic protein and activin membrane-bound inhibitor (BAMBI)
- Target
- BAMBI
- Molecular classification
- Transmembrane glycoprotein, Pseudoreceptor, Negative regulator of TGF-beta signaling, Other
01
Overview
Bone morphogenetic protein and activin membrane-bound inhibitor (BAMBI) is a transmembrane glycoprotein that resembles type I receptors of the transforming growth factor-beta (TGF-beta) family, but lacks an intracellular serine/threonine kinase domain, making it a pseudoreceptor[2][3][4]. BAMBI serves as a negative regulator of TGF-beta signaling, interacting with and modulating pathways involved in cell differentiation, proliferation, lipid metabolism, inflammation, and embryonic development[1][2][3]. It is implicated as a potential therapeutic target and biomarker in metabolic disease, cancer, inflammation, and other pathologies due to its varied roles in physiology and disease[1][2][5][6].
- Other names
- BMP and activin membrane-bound inhibitorBMP and activin membrane-bound inhibitor homologPseudoreceptor BAMBI
02
Mechanism of action
Negative modulation of TGF-beta pathway signaling by acting as a decoy receptor lacking the intracellular kinase domain, thus inhibiting downstream signaling transduction[2][3][4]. Modulation of Wnt and TGF-beta pathways in cell proliferation, immune response, and tumorigenesis[2].
03
Biological functions
Regulation of TGF-beta superfamily signalingNegative regulation of transforming growth factor-beta (TGF-beta) signalingModulation of adipogenesis (fat cell development)Regulation of inflammatory responsesRegulation of cell proliferation and differentiationRegulation of embryogenesisModulation of myogenesis (muscle stem cell function)Regulation of ovarian function
04
Disease associations
CancerObesity and metabolic diseaseInflammationNon-alcoholic fatty liver disease (NAFLD)DiabetesNeuroprotection (e.g., in spinal cord injury)Other
05
Safety considerations
No direct safety concerns reported for targeting BAMBI specifically; challenges may include broad physiological roles of TGF-beta signaling inhibition (e.g., possible effects on immune, metabolic, and tissue regeneration processes)[1][2].
06
Interacting drugs
None currently approved or well-established as direct modulators; research ongoing[1][2][5][6].
07
Biomarkers
BAMBI expression has been explored as a biomarker for:
- ObesityInflammatory states (e.g., bacterial infection)Cancer prognosis[1][2].
Beyond the preview
Go deeper on Bone morphogenetic protein and activin membrane-bound inhibitor (BAMBI).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bone morphogenetic protein and activin membrane-bound inhibitor (BAMBI).